Lipum Ab Stock Fundamentals
| LIPUM Stock | SEK 16.20 0.40 2.41% |
Lipum AB fundamentals help investors to digest information that contributes to Lipum AB's financial success or failures. It also enables traders to predict the movement of Lipum Stock. The fundamental analysis module provides a way to measure Lipum AB's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Lipum AB stock.
Lipum |
Lipum AB Company Return On Asset Analysis
Lipum AB's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Lipum AB Return On Asset | -0.91 |
Most of Lipum AB's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Lipum AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Based on the latest financial disclosure, Lipum AB has a Return On Asset of -0.9118. This is 89.58% lower than that of the Healthcare sector and 96.14% lower than that of the Biotechnology industry. The return on asset for all Sweden stocks is notably higher than that of the company.
Lipum AB Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Lipum AB's current stock value. Our valuation model uses many indicators to compare Lipum AB value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Lipum AB competition to find correlations between indicators driving Lipum AB's intrinsic value. More Info.Lipum AB is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Lipum AB's earnings, one of the primary drivers of an investment's value.Lipum Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lipum AB's direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Lipum AB could also be used in its relative valuation, which is a method of valuing Lipum AB by comparing valuation metrics of similar companies.Lipum AB is currently under evaluation in return on asset category among its peers.
Lipum Fundamentals
| Return On Equity | -1.81 | |||
| Return On Asset | -0.91 | |||
| Operating Margin | 117.68 % | |||
| Current Valuation | 98.1 M | |||
| Shares Outstanding | 7.65 M | |||
| Shares Owned By Insiders | 81.67 % | |||
| Shares Owned By Institutions | 8.14 % | |||
| Price To Book | 35.65 X | |||
| Price To Sales | 3,380 X | |||
| Gross Profit | (48.69 M) | |||
| EBITDA | (52.11 M) | |||
| Net Income | (52.26 M) | |||
| Total Debt | 1.57 M | |||
| Book Value Per Share | 0.59 X | |||
| Cash Flow From Operations | (34.3 M) | |||
| Earnings Per Share | (10.77) X | |||
| Target Price | 22.0 | |||
| Market Capitalization | 104.07 M | |||
| Total Asset | 49.66 M | |||
| Z Score | 36.3 | |||
| Net Asset | 49.66 M |
About Lipum AB Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Lipum AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lipum AB using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lipum AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Lipum AB , a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. The company was founded in 2010 and is headquartered in Ume, Sweden. Lipum AB is traded on Stockholm Stock Exchange in Sweden.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Lipum Stock Analysis
When running Lipum AB's price analysis, check to measure Lipum AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lipum AB is operating at the current time. Most of Lipum AB's value examination focuses on studying past and present price action to predict the probability of Lipum AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lipum AB's price. Additionally, you may evaluate how the addition of Lipum AB to your portfolios can decrease your overall portfolio volatility.